Recursion Pharmaceuticals

Recursion Pharmaceuticals Liabilities

The The Liabilities of Recursion Pharmaceuticals (RXRX) as of Nov 16, 2026 is 343.27 M USD. In the previous year, The Liabilities was 413.82 M USD — a change of -17.05% (lower).

Liabilities

343.27 MUSD

YoY

-17.05%

Last updated:

In 2025, Recursion Pharmaceuticals's total liabilities amounted to 343.27 M USD, a -17.05% difference from the 413.82 M USD total liabilities in the previous year.

The Recursion Pharmaceuticals Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
225.70 M USD
Jan 1, 2020
504.87 M USD
Jan 1, 2021
67.41 M USD
Jan 1, 2022
215.48 M USD
Jan 1, 2023
190.26 M USD
Jan 1, 2024
413.82 M USD
Jan 1, 2025
343.27 M USD
The Recursion Pharmaceuticals Liabilities history
YEARLiabilitiesYoY
343.27 MUSD-17.05%
413.82 MUSD+117.50%
190.26 MUSD-11.70%
215.48 MUSD+219.67%
67.41 MUSD-86.65%
504.87 MUSD+123.70%
225.70 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Recursion Pharmaceuticals's Liabilities

Recursion Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Recursion Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Recursion Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Recursion Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Recursion Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Recursion Pharmaceuticals stock

The Liabilities of Recursion Pharmaceuticals is 343.27 M USD in 2025.

The Liabilities of Recursion Pharmaceuticals changed from 413.82 M USD to 343.27 M USD, representing a -17.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals